To address both of these points, future studies will treat cyclin E overexpressing mice [31] with next-generation TNKS inhibitors in both chemopreventative and chemotherapeutic modalities to assess their benefit as single agents or in combination to prevent or treat lung cancer. This evidence concerns the gene TNKS and lung carcinoma.